Working... Menu
Trial record 1 of 1 for:    ted12337
Previous Study | Return to List | Next Study

Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients (SARMETA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01657214
Recruitment Status : Completed
First Posted : August 6, 2012
Last Update Posted : February 17, 2016
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

In the dose escalation: to determine the maximum tolerated dose (MTD) of SAR125844.

In the expansion cohort: to evaluate the preliminary anti-tumoral effect of SAR125844 in patients with measurable and MET gene amplification (including gastric cancer patients).

Secondary Objectives:

To characterize and confirm the global safety profile of SAR125844 including cumulative toxicities.

To assess preliminary antitumor activity of SAR125844. To explore the pharmacodynamic effects (PDy) of SAR125844. To evaluate the pharmacokinetic profile of SAR125844. To explore the relationship of MET gene amplification status with antitumor effects.

To evaluate other pharmacodynamic biomarkers.

Condition or disease Intervention/treatment Phase
Neoplasm Malignant Drug: SAR125844 Phase 1

Detailed Description:

For both cohorts, escalation and expansion, the duration of the study for one patient will include a period for inclusion of up to 3 weeks and a 4-week treatment cycle(s).The patient may continue treatment until disease progression, unacceptable toxicity or willingness to stop, followed by a minimum of 30-days follow-up.

If a patient treated in dose escalation part or in an expansion cohort, continues to benefit from the treatment at the time of Clinical Study Report, the patient can continue study treatment for a maximum of 1 year and will continue to undergo all assessments as per the study flowchart. Such patients will be followed at least until 30 days after the last IMP administration.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, Dose Escalation Study of Safety, Pharmacokinetic and Pharmacodynamic of SAR125844 Administered Weekly as Intravenous Infusion in Asian Adult Patients With Advanced Malignant Solid Tumors
Study Start Date : September 2012
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Arm Intervention/treatment
Experimental: Dose escalation
SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is >340 mg/m^2.
Drug: SAR125844

Pharmaceutical form:Concentrate for solution

Route of administration: intravenous

Primary Outcome Measures :
  1. - DOSE ESCALATION To determine the maximum tolerated dose (MTD) of SAR125844 [ Time Frame: At d28 of Cycle 1 of each treated patient, DLT is assessed ]
  2. - EXPANSION Cohort To evaluate the preliminary anti-tumoral effect of SAR125844 [ Time Frame: Antitumor activity is assessed at the end of Cycle 1, then every 2 cycles up to treatment discontinuation ]

Secondary Outcome Measures :
  1. Number of patients with treatment emergent events [ Time Frame: Up to a maximum of 2 years ]
  2. Assessment of PK parameter Cmax [ Time Frame: Up to a maximum of 2 years ]
  3. Assessment of PK parameter AUCs [ Time Frame: Up to a maximum of 2 years ]
  4. Assessment of PK parameter CL [ Time Frame: Up to a maximum of 2 years ]
  5. Assessment of PD parameter ShedMET [ Time Frame: Up to a maximum of 2 years ]
  6. Assessment of PD parameter HGF [ Time Frame: Up to a maximum of 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patients with solid tumor for which no standard therapy is available.
  • At the recommended dose (expansion cohort): only patients with measurable disease and MET gene amplification.

Exclusion criteria:

  • Patient less than 20 years old.
  • ECOG performance status >2.
  • Poor bone marrow reserve as defined by absolute neutrophils count <1.5 x 10^9/L or platelets <100 x 10^9/L.
  • Poor organ function as defined by one of the following:
  • Total bilirubin >1.5 x ULN.
  • AST, ALT, alkaline phosphatase >2.5 x ULN or >5 x ULN in case of documented liver metastasis.
  • Serum creatinine >1.5 x ULN, or serum creatinine between 1.0 and 1.5 x ULN associated with calculated creatinine clearance <60 mL/min.
  • Proteinuria >500mg/24h.
  • Pregnant or breast-feeding women.
  • Sexually active (males and females) who do not agree to use medically acceptable methods of contraception during the course of the study and for 3 months following discontinuation of study drug.
  • Female patients of childbearing potential must have a negative pregnancy test at screening.
  • Known or symptomatic brain metastasis (other than totally resected or previously pre-irradiated and no progressive/relapsing) or lepto-meningeal carcinomatosis.
  • No resolution of any specific toxicities (excluding alopecia) related to any prior anti-cancer therapy to grade ≤1 according to the NCI CTCAE v.4.03.
  • Wash out period of less than 3 weeks from previous antitumor therapy or any investigational treatment,(and less than 6 weeks in case of prior nitrozo-urea and or mitomycin C treatment).
  • Any surgery with major risk of bleeding performed less than 10 days prior to study treatment administration.
  • Any other severe underlying medical conditions, which could impair the ability to participate in the study.
  • Patients treated with potent CYP3A inhibitor.
  • Patients treated with potent and moderate CYP3A inducers.
  • Known hypersensitivity or any adverse event related to the study drug excipient (Captisol®).
  • Prior treatment with any MET inhibitor compound (selective or not).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01657214

Layout table for location information
Investigational Site Number 392001
Kashiwa-Shi, Japan
Investigational Site Number 392004
Suita-Shi, Japan
Investigational Site Number 392002
Sunto-Gun, Japan
Investigational Site Number 392003
Takatsuki-Shi, Japan
Korea, Republic of
Investigational Site Number 410001
Seoul, Korea, Republic of, 110-744
Investigational Site Number 410004
Seoul, Korea, Republic of, 120-752
Investigational Site Number 410003
Seoul, Korea, Republic of, 135-710
Investigational Site Number 410002
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT01657214     History of Changes
Other Study ID Numbers: TED12337
U1111-1126-7527 ( Other Identifier: UTN )
First Posted: August 6, 2012    Key Record Dates
Last Update Posted: February 17, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Layout table for MeSH terms